MUC2 (MRQ-18) Mouse Monoclonal Antibody
Specialties: Gastrointestinal (GI) Pathology
Mucins are a diverse group of complex, highly glycosylated extracellular proteins. Mucin 2 (MUC2) protects the gastric and intestinal epithelium from chemical and mechanical injury.1 Anti-MUC2 reactivity is normally seen in goblet cells of the small intestine and colon, and is associated with mucinous carcinomas, including those of the gastrointestinal tract and ovary.2-6 MUC2 immunohistochemistry is useful for identifying colonic, gastric and esophageal carcinomas.7-9
- Chaves, P et al. "Gastric and intestinal differentiation in Barrett's metaplasia and associated adenocarcinoma." Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus vol. 18,6 (2005): 383-7.
- Leteurtre, Emmanuelle et al. "Relationships between mucinous gastric carcinoma, MUC2 expression and survival." World journal of gastroenterology vol. 12,21 (2006): 3324-31.
- Mino-Kenudson, Mari et al. "Mucin expression in reactive gastropathy: an immunohistochemical analysis." Archives of pathology & laboratory medicine vol. 131,1 (2007): 86-90.
- Mizoshita, T et al. "Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon." Histology and histopathology vol. 22,3 (2007): 251-60.
- Hanski, C et al. "Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary." The Journal of pathology vol. 182,4 (1997): 385-91.
- Albarracin, C T et al. "Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma." Human pathology vol. 31,6 (2000): 672-7.
- O'Connell, Fionnuala P et al. "Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract." Archives of pathology & laboratory medicine vol. 129,3 (2005): 338-47.
- Park, Seog-Yun et al. "Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma." Archives of pathology & laboratory medicine vol. 131,10 (2007): 1561-7.
- Rakha, Emad A et al. "Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 18,10 (2005): 1295-304.
Specifications
- Reactivity: paraffin
- Control: Colon (Cytoplasmic)
- Dilution Range: 1:50-1:200 *
Package Inserts
IFU
- IVD Rev. 5.0 (CMC29121050)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 291M-14 |
| 0.5 mL concentrate | 291M-15 |
| 1.0 mL concentrate | 291M-16 |
| 1.0 mL predilute ready-to-use | 291M-17 |
| 7.0 mL predilute ready-to-use | 291M-18 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 291M-14 |
| 0.5 mL concentrate | 291M-15 |
| 1.0 mL concentrate | 291M-16 |
| 1.0 mL predilute ready-to-use | 291M-17 |
| 7.0 mL predilute ready-to-use | 291M-18 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 291M-14 |
| 0.5 mL concentrate | 291M-15 |
| 1.0 mL concentrate | 291M-16 |
| 1.0 mL predilute ready-to-use | 291M-17 |
| 7.0 mL predilute ready-to-use | 291M-18 |
For research use only (RUO) in Japan
| 0.1 mL concentrate (RUO) | 291M-14-RUO |
| 0.5 mL concentrate (RUO) | 291M-15-RUO |
| 1.0 mL concentrate (RUO) | 291M-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 291M-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 291M-18-RUO |
To request information on this product in additional countries, please click the button below.